Available Technologies
# of Displayed Technologies: 2 / 2
Applied Category Filter (Click To Remove): Vaccines
Revolutionizing Cancer Immunotherapy with Novel Chimeric B-cell Epitope Peptide Vaccines
TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.
The emergence of immune checkpoint inhibitors revolutionized cancer immunotherapy. Monoclonal antibodies targeting PD-1, PD-L1 and CTLA-4 have shown impressive clinical outcomes.
The Need
Despite their effectiveness, current monoclonal antibody treatments have limitations such as low response ra…
- College: College of Medicine (COM)
- Inventors: Kaumaya, Pravin
- Licensing Officer: Schultz, Teri
Novel Immunomodulators and Vaccine Adjuvants
TS-038032 — A class of compounds possessing potent immunomodulatory activity, to enhance the protection of vaccines against infectious agents.
While vaccines are commonly used today for a variety of diseases and have proven efficacious for disease prevention, some vaccines do not efficiently activate an immune response. About 10% of vaccinations fail to mount adequate antibody levels to routine vaccinations. Also, many viruses rapidly mu…
- College: College of Medicine (COM)
- Inventors: Satoskar, Abhay; Ainslie, Kristy; Bachelder, Eric; Fuchs, James; Kinghorn, Alan "Dr. A. Douglas Kinghorn"; Parinandi, Narasimham
- Licensing Officer: Schultz, Teri
